tradingkey.logo

Imdelltra® Demonstrated Superior Overall Survival In Small Cell Lung Cancer

ReutersApr 11, 2025 1:28 PM

- Amgen Inc AMGN.O:

  • IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

  • AMGEN INC - SAFETY PROFILE FOR IMDELLTRA WAS CONSISTENT WITH ITS KNOWN PROFILE.

  • AMGEN INC: GLOBAL PHASE 3 DELLPHI-304 CLINICAL TRIAL MET ITS PRIMARY ENDPOINT AT A PLANNED INTERIM ANALYSIS

  • AMGEN: IMDELLTRA SHOWED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS VERSUS LOCAL STANDARD-OF-CARE CHEMOTHERAPY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI